The abstract is read at the publisher; the summary is JClub's.
Effective activation frequencies for Reactome pathways using N/T-exclusive genes resolve six molecular subtypes in prostate adenocarcinoma tumors (PRAD, n=499), covering 406 tumors (81.4%).
- Why it matters: Conventional pathway enrichment averages over many annotated genes and relies on arbitrary thresholds, diluting signals tied to the normal-to-tumor transition and limiting pathway-level quantification across cancers.
- What they did: They compute per-sample effective N/T pathway activation frequencies as the fraction of annotated N/T genes active, then use cohort averages, hierarchical clustering, and an MST on pathway-frequency vectors.
- The result: Across PRAD, LUAD, LIHC, and GBM, normal-tissue protection hierarchies align with tumor progression programs, with shared protection in DNA repair/cell cycle/RTK and tissue-specific pathway losses and gains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.